SIRT4-Mediated Deacetylation of PRDX3 Attenuates Liver Ischemia Reperfusion Injury by Suppressing Ferroptosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sirtuin 4 (SIRT4) protects against liver ischemia-reperfusion injury (LIRI) by inhibiting ferroptosis. Targeting the SIRT4-PRDX3 pathway offers a novel therapeutic strategy for LIRI.
Area Of Science
- Hepatology
- Molecular Biology
- Transplantation Immunology
Background
- Liver ischemia-reperfusion injury (LIRI) significantly impacts liver transplantation outcomes.
- The role of Sirtuin 4 (SIRT4) in LIRI pathogenesis remains largely unexplored.
- SIRT4 is known to participate in diverse post-translational modifications.
Purpose Of The Study
- To elucidate the specific role and mechanism of SIRT4 in the development of LIRI.
- To investigate SIRT4 as a potential therapeutic target for mitigating LIRI.
- To explore the SIRT4-PRDX3 interaction in the context of liver injury.
Main Methods
- Utilized SIRT4 knockout and liver-specific overexpression mouse models.
- Employed alpha mouse liver 12 (AML12) cells under hypoxia-reoxygenation (H/R) conditions.
- Investigated the interaction between SIRT4 and peroxiredoxins 3 (PRDX3) using biochemical assays and ferroptosis inhibitors.
Main Results
- SIRT4 expression was reduced in LIRI models, liver transplant patients, and H/R-treated AML12 cells.
- SIRT4 deficiency aggravated liver injury and ferroptosis, while overexpression conferred protection.
- SIRT4 deacetylated PRDX3 at lysine 92, inhibiting ferroptosis and protecting against LIRI.
Conclusions
- The SIRT4-PRDX3 axis is a critical regulator of ferroptosis in LIRI.
- SIRT4 exhibits a protective effect against LIRI, mediated by PRDX3 deacetylation.
- Liver-targeted mRNA delivery of SIRT4 demonstrates therapeutic potential for LIRI.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
